Disagreement between site investigators and clinical event committees is common and can affect trial results  by Mahaffey, K.W. et al.
184A ABSTRACTS - Oral JACC Fehrear)' 1998 
Results: There WGS a total of 296 qualifying episodes of AF from 42 
recordings, The table summarlsos the comparisons between day and night- 
time episodes, HR prior AF was slower (p < 0,0001; WIIcoxon test) during 
the night, but other differences were non-significant, 
Comp~lrmon between mode of AF on~ot nt night and during day 
Number Mean HR A mann HR 'NNN' 'NSN' 'NL~' 
D~,, t31 75,0 bpm ,oO,1% 77,i% 2,~% 2,3% 
N igh~ 105 02,2 bpm ~G,3% 0?,0% 0.7% 3,0% 
Concl~ston: Apart from underlying HR, the mode el AF initiation does not 
differ during ~ympathetlG and parasympathetic predominance, 
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~ Pravalan©o f the 8ympathetle Influence Before 
Atrial Fibrillation Onset In the So-Called "Vagal 
Paroxysmal Atrial Fibrillation Patients" 
A, Capu¢cl, G, Coccngna t , A, Santarelll, S, Baulso, G, Borlant, Cardiology 
Co, of, G~ne~l Hospital Pla~nza, Italy; t testtf~te of Ne~tmtegy of Bolc~jna, 
In~tlftJte of Ca~tolngy Bologna, ~ Italy 
To evaluate the Influence of the autonomic nee/age eyBtom (ANS) on perex. 
ysmat ~trlal fibrillation (PAF) onset in putlonte (pte) wtth either n~tum:tt or 
"vaunt p~ttam", we studied 45 pie with a poligmphlo analyeie of steep and 
Halter monitoring after a complete druga wash.out, We ueod a Marquette 
sarlea 8000 Hotter with heart rate variability (HRV) software and defined the 
low freqoenglos (LF) (0,04-0,15 Ha) and high frequencies (HF) (0,15-0,40 
H~) ratio for all the sloop stages and at the PAF enact (tO mtmffea before), 
Spectral mo~sures wore comp~ted over 2 minutes e~mplee, 25 pts had no 
~trial fibrillation eptsodss, 5 pts had continues atrial fibrillation rhythm, Tee 
15 pts with docomonted PAF onset were selected for power spectral enaiysis 
of the Hotter recordings. 
W~lko Ph~o 1 -~ Phase 3-4 REM 
• LF/HF 214 t 0,e3" aUG 1: 010" 1 01 t 0 42' 1 52 !: 0 38 
• LF/HF st PAF onset 1 85 t O,5S 1 41 t 0,2~1 ~ 216 ~t 030 1 54 t 0 58 
• n PAF on~M 14 12 ~ 3 
• ~ p - 0 ,0001 vs 1--2 and 3--4; " ~ p • 00001 vs REM~ ' ~ p. 0 0OS v.~ REM ~ = p.  
O 0001 vs bssnl 
In conclusion, pts with apparent "vngal pattern" of PAF present a regular 
prevalence of the sympsthetlc and parasympathetic omponents during the 
different sleep stages. A sympathetic influence before PAF onset is prevalent 
expcclally during the superficial sloop phase 1-2, 
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~3--6-5--I Atrial Arrhythmlas Early After Cardloverslon Predict 
Recurrence of Atrial Fibrillation 
TIN, Maounis ~ , E, Kymzi t , E, Evgenladou ~ , K, Katsares ~ , E. Biltanou °, 
V, VasstllkosL A, Mnnolis ~ , D,V, Cokkinos ~ . 1st Cardiology Department, 
Greece; ~Onassis Cardiac Surgery Center, Greece: "~ Tzanio Hospital, 
Athen.~ Greece 
Background, The recurrence of atrial fibrillation (AF) alter electrical cardiover- 
ston (ECV) is frequent and affected by many factors, We assessed whether 
tho atrial ectoptc activity found in a Halter recording (HR) immediately after 
ECV for AF is predictive of future recurrence of this anhythmta. 
Methods: A total of 53 patients (pta) (31 mates, mean age 58 ± 12) with 
AF of varying duration and etiology, underwent a 24 hour HR immediately 
alter successful ECV. All had undergone an echocerdiogrephic evaluation to 
estimate left atrial size (LA), They were followed for one year after EC, on the 
same medication that they were receiving at the time of ECV (amiodarone 14, 
Prepafenone: 16, both: 12, sotalol: 11). From the HR the total number of atrial 
premature cemptexos (APCs) of the first six hours (6HAPs) end the average 
number of APCs per hour of the whole recording (HAPCs) were calculated 
and for statistical analysis their natural logarithms (In) wore computed. The 
endpoint o! the study was recurrence of the errhy~hmla t one year. 
Results: A total of 25 pts (47%) had AF recurrence at one year, Signifi- 
cant differences were found in the comparison of In6HAPCs and [nHAPCs 
between the two groups, while left atrial size (LA) or medication were not 
significantly differeht, 
AF roc, LA HAPCs (; \PCs In6APCs InHAPCs 
Yes 4.86 ~ 0,7 55~ 113 393 ~854 5,0~ 1.3 30 ~.- 13 
No 5.06 L 0.9 6 ~: 5 42 i 40 33 L 1 2" 1.4 ~: 1.1" 
'p - 0.0001 
The recording of 10 APCs per hour in the HR after ECV had a sensitivity 
of 70%, a specificity of 77%, a positive predictive value of 70% and negative 
predictive value of 77% for recurrence of AF in the first year after ECV. 
Conclusion: The number of APCs in n HR ¢tfter ECV for AF can Identify 
pts at high dek for recurrence of AF who might need optimization or change 
of treatment, oven before discharge, and more careful follow-up 
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~ Identlfloatlon of Hypertensive Patients With Atrial 
Fibrillation: Loft Atrial Size, Signal Averaged 
P-Wave, or Beth? 
A, Votgmon, S,L, Pinskl, S, Furmanov, P,A, S,ntoccL R,G, Tmhman, 
Rush.Presbyterian.St, Lc/ko~, Mr~l/cal Center, Chicago, IL, USA 
Background: Hypertension Is the most common cause o! atrial fibrillation 
(AF) In clinical practice, The duration of the P wave in the signal.averaged 
electrocardiogram (pSAECG) has b~en oso¢~ to identify pta at risk for AF, but 
Its valise In hyportonelvo heart dlsoaso h~a not been apeclrma!ly e~essed, 
Methods: We compared the diagnostic performance (ROC cgw~a) of the 
t01t etfl~tl (LA) ol=e and the DSAECG In 31 pts with hypertensive heart d i~se  
(18 with a histow o! AF), The pSAECG was ~¢orqecl in orthogonal XY~ leads 
with Marquette Etoctronies, Ino, software, 
Respite: Beth tests identified pts with AF, hot the overall pertom~ance of 
LA ei~o wan eupedor (~rea ondor the RC~ e~n/e 0,81 vs  0,70; 2.tailed p 
0,~0) The h0St CutOff Of LA ~44 mm had sensitivity e! 61% and specttclty el 
85% The boM cutoff ef hltered P wave :: 150 ms had sensilivity of 61% and 
Sp0clti~ity Of 70%, The combination of both signs had a sensitivity el 2~.  
nnd a specificity of 92% (only 1 of the 13 pie without AF had both signs). 
I- Specificity 
Conclusions: pSAECG does not appear to be particularly efficient in 
identifying hypertensives with AF. Its main clinical value may reside in its use 
in combination with other clinical markers, like LA size. 
New Findings Into the Use of GplllMilla 
Receptor Antagonists: Highlighted Abstract 
Session With Discussion of Current 
Perspectives 
Tuesday, March 31, 1998, 8:30 a.m.-lO:O0 a.m. 
Georgia World Congress Center, Lecture Hall 2 
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~-3-7--2-1 Disagreement Between Site Investigators and 
Clinical Event Committees is Common and Can 
Affect Trial Results 
K.W. Mahaftey, B.E. Tardiff, CB. Granger, K.L Lee, R.A. Harrington, 
E,J. Topoi, R,M, Califf, Duke Clinical Research Institute, Durham, NC, 
USA 
Background," A centralized Clinical Events Committee (CEC) review process 
was used to adjudicate suspected clinical endpoint events in four large. 
randomized multicenter clinical tdals. 
Methods: We compared the pdmary endpoint event rates determined by 
data on the Case Report Form (CRF) with the event rates reported by the 
CEC (see table). 
Results: The event rates reported by the CEC were typically higher than 
those rep,.rted by investigators on the CRF. The effect on the statistical 
CRF CEC 
Control Study P Control Study P 
EPIC 12.4% 9,0% 0.120 12.8% 8.3% 0.009 
IMPACT-II 7.8% 5.5% 0.018 11.4% 9.2% 0.063 
GUSTO-lib 9.6% 84% 0.016 9.8% 8,9% 0.058 
PURSUIT 10.0% 8.0% 0.0007 15.7% 14.2% 0.042 
JACC Fcbru;~, I*;q,~ AI~,~TRA(I",~ - (~,1 185A 
signiflcBnco of the treatment eff(~-t we6 dramat¢, ,noreamng the percetvecl 
I~nofit in EPIC a.d decreasing the benefit in IMPACT.II, GUSTO-lib. and 
PURSUIT, 
Cor~l~:  A ,~ntral CK~ud~2at~)n pro~esS can have a substantial impact 
oll IN) ovoratl event rate5 and f.al results Differences m event f~f(~ may 
reflect sy~emat¢: differences in id~t i~ l i~t  Of ~.spe¢t~l ~vtmte, aR~lca~n 
of cflt(,~ tnaL~d for ~/eet~ sLrch as reinfar~o0, or und~mrandlng Of the most 
trine, ally mlmrant me~sum~ The~ finc~ng~ ve  important in'~!icaffo~s for 
f.tum ~a|s, 
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~ Sul!tll!nlld Pt#Ie!M GP IIb/!lla IB!ockade With Onl! 
Ofbofllmn: !.~edm P h a ~ l ~  Ruu!ts of the 
SOAR StY ,  
J J, Ferguso~. PC, IDe~lwanm, 01  Kem~akeS, D Filzgerak:L R.J, A~r~,  
DM, Bums, B.S. ~ k L  ~ ~ ~ tnse~le, Houston. TX a,"~ G, 
~ '~k~ SOAR (Safe~/el (~tx~t~n in Acute Coronary Research) m 
a ran(~om!zeOL ~ study ~ to compare four ~ge 
~S oi the oral i~atelet GP !roA!la J~biter Orbofiban to p l~ in pahenls 
with ~ angina m recent (>6 hours b~ ~ l~ houm) myocardial infarc- 
tion. Patients (n = 259) were r a ~  to recewe Odbofiban (30, 40, 50 
mg BID or 50 mg QO) O, I~¢ebo re, up to 3 montt'~ All pa~ents recetved 
coz~-~tant as~nn (162 mo~6~y) 
~ "  E~ vtvo m~t~ el platetet ~ to agon~l (20. M ADP) 
wa~ meastm~l on [~/1  ax~l al 2 and 4 ~ (n = 145). 
Res~/~: The ~t t~n of plaletet aggregatm~ tO ADP at trough and peak 
following 2 weeks el dosteg were smear to IP, e 4 week results show~ befaw: 
- 
Conctus~n; Orbofiban produced a dose-related increase in ADP 20~,M 
platetet aggregabon inhibition. Target therapeutic ranges of ptatelet inh~b(t~on 
(60-80% arYJ 40-60% throughout he desmg interval) are achievable w~th 
BID dosing 
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-~  Clinical of Integrilin in Unstable Angina is Efficacy 
Accompanied by a Modest Increase in Hemorrhagic 
Risk: The PURSUIT Tdal 
AM. Lincoff. R.A. Hmnngton. R.M. Caltff. LG  Berdan. M.M. Kitt, 
8.D. Weathedy. N.S. Kleiman. E.J. Topoi. For the PURSUIT Investigators. 
Cleveland Clinic Foundation. Cleveland. OH and Duke Clinical Research 
Institute. Durham, NC, USA 
Background: Integrilin" (Eptifibatide). a cyclic KGD pept~de inhibitor of the 
ptatelet GP lib/Ilia receptor, was evaluated in the randomized, double-blind. 
placebo-contrelled PURSUIT trial among 10,948 pts with unstable angina, 
Eptifibatide treatment (180 pg/kg bolus, 2.0 pg/kg/min infusion) for up to 
72-96 hre was assOCiated with an absolute 1.5°,'o reduction in the incidence 
of death or MI within 30 days (15.7 vs 14.2%, p = 0.0424). 
Methods: Bleeding complications during the hospitalization penod were 
defined as severe (intracraniat or causing hemodynamic v'ompromise), rood- 
erate (requiring transfusion), or mild (all other). 
Resuffs/Conclusions: Moderate or severe bleeding (most often at s~tes 
of vascular access) was increased with eptifibatide, particularly in pts who 
did not require bypass surgery. Thus, reduction in ischemic events with 
PlaCebO Eptifibatide 
Moderate or Severe Breed 9.9";, 128%" 
Moderate or Severe Bleed w/o CABG 2.0% 52% 
RBC or Whole Blood Transfusion 9.3% 11.8% 
Transfusion w/o CASG 1.8% 44¢'" 
Intracranial Bteed 0.09% 0.11% 
"p. 00001 
eptifibatl~ i~ a.Chlevecl aLt ~ CO~t of a modest inc f (~ if~ C1 .'~K'.alty -~ ,l]~dlCaPff 
bleeding and transfusionS, but no inCre~se ~n intracrantal herrnO~t~ge 
9:30 
[8~ ThfombocytOp(mll Wlth GP .bs111g l.hlbltom: 
. . . . .  A l~avA.aly=l= 
R,P Gi~l!ano, R,R, Hy~tt, J~  8ng/~m ar~ ~nen~ ~ ~ ~rva~ 
Med~ca~ SoP, eel, Bo~ton, M4, USA 
~ m  (GP) Ilb/llla ~ ,  Sun-~a~ ~fa r~Oat'mg rates to 
and between agents fS sparse, 
Me~."  We pedot'me~ ,~ meta.analylsis Of all placebO-cOntrolted 
It-Ill clinK;a! teals of GP llb~ll!a~ mh~tom using the ~ n  ~ La~ 
ranOom effects ~1 ~ estimate the odds ratio of ~.Plt foe ~ V~ pl~-'ebo, 
S~gte~p analyses efrat*tied ~ drug ~nd requited use Ol hepam~ were amo 
pe~ormed, 
Re,J~/t~, Data on ~ Pit was avaitable for 25 0f the 26 teals ~ AIP 
solute rates 0f ;Pit ranged from 0~-1~.  depending on the clinical scena,o 
anO drag. The ovu,af! ~ rate of .~Plt for 13.093 I~1~'116 treated 
GP Iib/llla mh*bffo~ was 23% Odo's ratios with 95% CIs for risk ot ~Pff am 
shown below tar sefeete~ drugs, teals with vs, without fequIft~ hepann, and 
the overall mela.ana~m. 
C.onc/us~rm.' Use of GP Ill.Ilia inll~b~ors increases ~ne nsk Of ~PIt by 
apprcmimately 42% compared to ptacebo. Currenl sludies do not demonstrate 
s~gmficant differences between drugs, or in the pr~e or ~nce  ot 
hepann. Hepann, in comb4nation wffh a GP lib/Ilia rob, biter, lP¢~ases 
obsenmd absolute rate of ~.PIL but does not synergmtcally increase ~e ns~. 
gts" OR 95%Cf 
A~cr~xmab 6.342 t 76 (O 92, 3 37l 
"13r~'~an 7,158 I 63 (0 94. 2611 
Ep~fibat~e 4618 104 (060, t 80) 
Lam~bart 3.000 O 63 (020, 3 49) 
Prepann requ;red 12.761 1 38 10 88. 2. f 6) 
hepann not required 8.799 1 46 (092 2 32) 
Air treats 215.50 f42 ( f 07, ! B9f 
" rn~s  all placebo anO treate-.t ~S 
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B~- - - -~  Value of  in Predicting Therapeutic Troponins 
Efficacy of  Abc ix imab in Patients With Unstable 
Angina 
CW Harem, C Heeschen. 8.U. Getclmann, E 8amathan, M.L S,moons ~ 
For the CAPTURE InveStigators; Umversrty Hospdal Eppendort, Hamburg, 
Germany, ' Erasmus Unwermty Rotterdam. The Net,~erlancls 
Background: In patmnts (pts) wffh acute corenaw syndromes mc'roemboliza- 
t~on from ruptured atheroseterotic plaques may cause minor myocardial infury 
detectable by c=rcuta~ng troponms. This was shown to be assocmted with an 
adverse short and long term outcome. The CAPTURE teal demonslrated that 
platelet inhibition with abetximab reduces risk for myocardial infarction (AMI) 
at~J death in pts w,h refractory unstable angina p,or to and after PTCA. 
The pre~em study therefore invest~gated whether troponin T (cTnT) allows 
to predict this benefit, 
Methods and Resuffs: In 226 of 546 (41%) pts receiving aboximab and 
219 of 547 (40%) pts recewmg placebo cTnT L.0.t0 noJml) was found on 
study entq/. Event rates (death, AMI) dunng the 24 to 36 hours treatment 
phase before coronary interventions: 
cTnT nag CTnT pos p-value 
aboxrmaD 06% 0.9% ns 
Placebo O 9°¢' 4 1% p = 003 
p-v..~mue n:; p = 0 03 
Ounng the following PTCA abciximab reduced nsk in cTnT pos, as well 
as cTnT neg. pts (4.8% placebo vs. 19%. p = 0.04) 
Conctumons: cTnT identifies pts w~th unstable angina who benefit from 
abciximab through eliminating exCessive nsk prior to PTCA. Therefore. it 
may serve as a marker to initiate this treatment. All pts benefit equally from 
abeiximab during interventions, 
